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Objective. To assess the effectiveness of various therapeutic hip preservation strategies on patients with nontraumatic osteonecrosis
of the femoral head (ONFH).Design. This is a systematic review of previous literature and in-depth Bayesian networkmeta-analysis
of randomized controlled trials (RCTs) to compare the clinical effect of various operation methods and one physical intervention
(extracorporeal shockwave). Data Sources. Electronic literature, for studies published up to December 2017, was collected from
PubMed, Medline, and the Cochrane Library. Study Selection. We selected RCTs on patients with ONFH. Treatment methods
included extracorporeal shockwave (ESW), core decompression (CD), multiple drilling decompression (DD), vascularized fibular
grafting (VFG), free-vascularized fibular grafting (FVFG), inverted femoral head grafting (IFHG), vascular iliac pedicle bone
grafting (VIPBG), osteotomy, and tantalum implantation (TI). Outcome. The primary outcome was Harris score; the secondary
outcome was Harris hip score (HHS), including total hip arthroplasty requirement (THA) and progression to collapse. Results.
A total of 14 randomized controlled trials were investigated. ESW had the highest improvement on Harris score (probability best
52%), followed by VFG (probability was 38%). In the meanwhile, VFG also proved to be superior in reducing the failure rates of
treatment (probability lowest 59%), followed by ESW (probability lowest 24%). In femoral necrosis stage-II, VFG achieved the
highest probability in preventing treatment failures (52%) and showed better performance in reducing treatment failure rates than
CD. Conclusion. ESW therapy (ESWT) is the most effective intervention to improve HHS, and VFG shows superior effect on
reducing treatment failure rates.
1. Introduction
Osteonecrosis of the femoral head (ONFH) is a debilitating
disorder with a considerably high incidence in individuals
aged between the third and fifth decades of life. In the United
States, ONFH is reported to affect 20,000 patients each year,
and it is estimated that more than 10% of ONFN patients
eventually required total hip arthroplasties (THA) annually
[1]. ONFH is histologically characterized by insufficient sup-
ply of blood, death of osteocytes, and bone marrow cells, as
well as progressive structure damage of involved bones, which
typically follows a progressive course leading to femoral head
collapse and hip joint destruction. Therefore, how to retard
the progression of ONFH is always a research hotspot.
The principle of ONFH treatment includes the termina-
tion of pathologic progression and the restoring of weight-
bearing capacity. Nowadays, the treatment and management
for ONFH consists of conservative and surgical approaches.
In a large number of studies, the clinical effect of ESWTwhich
was assessed from a comprehensive perspective showed
better effect than other conservative therapeutic methods [2,
3]. Besides, some RCT researches were designed to compare
different surgical interventions for ONFH, including CD,
DD, bone transplantation (VFG, FVFG, VIPBG, and IFHG),
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Osteotomy, and TI. These surgical interventions have been
applied to avoid the most invasive intervention: total hip
arthroplasty (THA). Core decompression, which is strictly
limited to the treatment for early stages of ONFH before
femoral head collapse [4], is now one of the most frequently
used interventions and offers effective outcomes. However,
some studies manifested that vascularized bone grafting (e.g.,
VFG, VIPBG) was superior to other treatments in clinical
outcomes, radiographic findings, and durability of treatments
[5, 6], though the operation method of grafting process and
the location of the grafts may have a significant influence
on the therapeutic effect. Above all, the optimal intervention
to preserve the femoral head remains controversial. In this
study, a Bayesian network meta-analysis method was used
for the quantitative comparison of different surgical inter-
ventions and ESWT to determine the optimal treatment for
ONFH.
2. Method
2.1. Data Sources and Searches. We searched literature pub-
lished between 1980 and 2017 in three electronic databases
(Medline, PubMed, and the Cochrane Library) for ran-
domized clinical trials investigating operation methods for
ONFH, with Medical Subject Headings (MeSH) and text
words.
For the purpose of Bayesian network meta-analysis, the
search extracted trials comparing ESW, VFG, FVFG, CD,
DD, IFHG, TI, osteotomy, and VIPBG. The trials involving
cellular therapy or biomaterials were excluded.
2.2. Study Selection. We included randomized, parallel group
design clinical trials comparing the effects of chosen opera-
tion methods and one physical intervention (ESW).
Inclusion criteria for studies were as follows: (1) the
study should be randomized, parallel group design clinical
trial; (2) the study should focus on ONFH; (3) the included
studies should report at least one of the three outcomes: the
improvement of Harris score and the frequency that hips
required THA or underwent collapse of the femoral head
after intervention.
Exclusion criteria were as follows: (1) the study was not a
RCT design; (2) the study included non-ONFH patients; (3)
the study combined cell-therapy effect with surgical options
(e.g., VFGplusmesenchymal stem cell implantation). Eligible
studies should be published as full-length articles or letters in
peer-reviewed journals.
2.3. Data Extraction and Quality Assessment. Two investi-
gators independently extracted the following information:
study design; name of the first author, publication year;
sample size, patients’ characteristics; interventions; compar-
isons; outcomes (postoperative Harris score and treatment
failure rate) and follow-up. Two investigators independently
evaluated the methodological quality of eligible RCTs by the
Cochrane Collaboration’s tool [7] for assessing risk of bias on
the basis of (1) random sequence generation, (2) allocation
concealment, (3) blinding of participants and personnel, (4)
blinding of outcome assessment, (5) incomplete outcome
data, (6) selective reporting, and (7) other sources of bias.
2.4. Outcome Assessment. HHS and treatment failure rates
were regarded as the outcome of the included RCTs. HHS
includes four subscales: (1) range of motion, (2) joint activity,
(3) pain, and (4) absence of deformity. A higher score indi-
cates a better treatment outcome. Treatment failure rates
included the frequency of THA requirement and the collapse
of the femoral head after intervention. If both events were
reported in RCTs, we chose the outcomes with greater
number.
2.5. Statistical Methods. Quantitative data of each eligible
study were first extracted in a spreadsheet. We analyzed two
treatment outcomes separately (HHS and treatment failure
rates). STATA (version 13.0, StataCorp LLC,TX, USA) and
the GeMTC R package (version 3.2.3, R Development Core
Team/R Foundation for Statistical Computing, Vienna, Aus-
tria) were used to perform network meta-analysis with
Bayesian hierarchical random-effects model [8]. The ran-
dom-effects model allowed the heterogeneity among tri-
als on the assumption that treatment effects originated
from a normal distribution. Markov Chain Monte Carlo
(MCMC) simulation method was used to calculate the
posterior distributions of the nodes in Bayesian network
frame. Noninformative priors with vague normal (mean 0,
variance 10 000) and uniform (0-2) prior distributions for
outcomes such as HHS and treatment failure rates were
performed [8]. Sensitivity analysis was performed to examine
the effects of different operation methods. We generated
100000 simulations for each initial value, and the first 50000
simulations were discarded. Convergence was assessed by
Brooks-Gelman-Rubin method. The median of the posterior
was the point estimate and the corresponding 95% credible
intervals using the 2.5th and 97.5th percentiles of the posterior
distribution were reported as 95% credibility intervals [9].
Inconsistency was evaluated in a loop which connected
three treatments [10]. We used node splitting method to
evaluate the inconsistency of network model [11, 12]. A parti-
cular comparison based on direct and indirect evidence was
performed, in which Bayesian P>0.05 was regarded as insig-
nificant [12].The probability of each treatment being the best
was calculated to provide a more comprehensible measure
of treatment efficacy on the basis of its posterior probability.
The plots of ranking probabilities (rankograms) illustrated
the order of treatments for each outcome [13].
Potential publication bias was assessed by visual
inspection of comparison-adjusted funnel plot [14–16]. The
Cochran’s Q (X2) and the I2 statistical test were calculated to
test for statistical heterogeneity [17].
3. Results
3.1. Characteristics andQuality Evaluation of Included Studies.
We retrieved 1209 related publications in total, among which
292 duplications, 140 letters or reviews, and 163 non-English
publications were immediately eliminated. 584 publications
were excluded by screening their titles and abstracts. The
BioMed Research International 3
Identiﬁcation Screening Eligibility Included
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Figure 1: PRISMA flowchart illustrating the selection of studies included in this study.
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Allocation concealment (selection bias) 
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Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias) 
Selective reporting (reporting bias)
Other bias
Low risk of bias
0% 25% 50% 75% 100%
Unclear risk of bias
High risk of bias
Figure 2: Risk of bias graph for each included study.
entire process of literature searching and screening for NMA
was illustrated in Figure 1. With the full-text assessment, 14
RCTs with a number of 1298 patients were enrolled into our
analysis. Main study endpoints included HHS, the treatment
failure rates of femoral necrosis in total stage and stage-II.
Baseline characteristics of the 14 studies were presented in
Table 1. All of the included studies were RCTs; the overall
quality of included studies was embodied in Figure 2.
3.2. Network Meta-Analysis of HHS. 10 two-arm RCT studies
reported the HHS, recruiting 538 patients (Figure 3(a)).
These studies were incorporated into the present network
Bayesian model. The mean duration of follow-up was 22
months. VFG was the most frequently studied intervention,
and the comparisons between VFG and FVFG were more
than those in other studies. In the direct pairwise compar-
isons, enhancement for VFG was statistically significant as
compared with FVFG (MD=16, 95% CrI [2.3, 29]). Other
pairwise comparisons did not show significant outcome.
In random-effects relative forest plots, enhancement was
detected with statistical significance for ESW versus DD (MD
= 29, 95% CrI [1.6, 57]), VFG versus DD, FVFG, and IFHG
(MD= 28, 95% CrI [6.8, 49]; MD = 16, 95%CrI [2.3, 29]; MD
= 39, 95% CrI [0.56, 78]); there was no significant effect on
improving HHS among the other interventions (Figure 4(a)).
In rankograms (Figure 6(a)), ESWwas estimated to have a
55.4% chance of being the best intervention for the treatments
of femoral necrosis, followed by VFG (38.6%). From the
perspective of improving HHS, our study revealed that ESW
therapy and VFG technique were the best two options for hip
preservation treatments in terms of improving HHS.
3.3. Network Meta-Analysis of the Treatment Failure Rates in
Femoral Necrosis Total Stage. In our study, treatment failure
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(a) Harris hip score (b) Treatment failure rates
(c) Treatment failure rates in stage-II
Figure 3:Network comparisons for (a) HHS, (b) the treatment failure rates (Collapse&THAprogression), and (c) the treatment failure
rates (Collapse & THA progression) in stage-II included in the analyses. THA: total hip arthroplasty; CD: core decompression; ESWT:
extracorporeal shockwave;DD:multiple drilling decompression; VFG: vascularized fibular grafting; FVFG: free-vascularized fibular grafting;
IFHG: inverted femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone grafting; TI: tantalum implantation.
outcomes included collapse and THA progression. There
were 13 literature sources that described the treatment failure
rates, recruiting 1277 patients (Figure 3(b)). In the direct
pairwise comparison, the overall effect showed that VFG had
a statistically lower treatment failure rate as compared to CD
(OR = 0.16, 95% CrI [0.048, 0.39]), while there was no signif-
icant difference among other interventions (Figure 4(b)).
In random-effects relative forest plots, VFG had a lower
treatment failure rate (OR = 0.16, 95%CrI [0.048, 0.39]; OR =
0.12, 95% CrI [0.042, 0.37]; OR = 0.18, 95% CrI [0.034, 0.94])
compared with CD, FVFG, and osteotomy for total stage
(Figure 5(b)).Therewas no significant difference in treatment
failure rates for other methods. Rankograms indicated that
VFG had the lowest probability for the progression to THA
and femoral collapse. Besides, ESW also showed a low prob-
ability for the progression to treatment failures (Figure 6(b)).
3.4. Network Meta-Analysis of the Treatment Failure Rates
in Femoral Necrosis Stage-II. A total of 13 studies described
the treatment failure rates in femoral necrosis stage-II (Fig-
ure 3(c)).Theoverall effect showed that onlyVFGhad a statis-
tically lower failure rate as comparedwithCD (OR=0.13, 95%
CrI [0.0036, 1.0]) in the direct pairwise NMA (Figure 4(c)).
Moreover, we found that VFG tended to show lower failure
rates than FVFG in random-effects relative forest plots (OR
= 0.090, 95% CrI [0.0053, 1.1]) (Figure 5(c)). Rankograms
indicated that VFG was the optimal intervention in the
prevention of treatment failures (Figure 6(c)).
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(a) Harris hip scores (b) Treatment failure rate
(c) Treatment failure rates in femoral necrosis stage-II
Figure 4: Forest plots of direct comparison of (a) HHS and (b) the treatment failure rates included in the network meta-analysis in a
Bayesian framework. CD: core decompression; ESWT: extracorporeal shock wave; DD: multiple drilling decompression; VFG: vascularized
fibular grafting; FVFG: free-vascularized fibular grafting; IFHG: inverted femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone
grafting; TI: tantalum implantation.
(a) Harris hip score (b) Treatment failure rates (c) Treatment failure rates in stage-II
Figure 5: Relative forest plots of each pairwise comparison of (a) HHS, (b) the treatment failure rates, and (c) the treatment failure
rates in stage-II included in the network meta-analysis in a Bayesian framework. THA: total hip arthroplasty; CD: core decompression;
ESWT: extracorporeal shock wave; DD: multiple drilling decompression; VFG: vascularized fibular grafting; FVFG: free-vascularized fibular
grafting; IFHG: inverted femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone grafting; TI: tantalum implantation.
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Figure 6:Rank probability curves for (a) HHS, (b) the treatment failure rates, and (c) the treatment failure rates in stage-II.Distribution
of probabilities for each treatment is ranked at different positions for each outcome. CD: core decompression; ESWT: extracorporeal shock
wave; DD: multiple drilling decompression; VFG: vascularized fibular grafting; FVFG: free-vascularized fibular grafting; IFHG: inverted
femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone grafting; TI: tantalum implantation.
3.5. Inconsistence Check. Statistical consistency between
direct and indirect comparisons for HHS and treatment fail-
ure rates in total stage and stage-II was analyzed in Figure 7.
Theoverall networkwas highly consistent, without significant
differences between direct and indirect comparisons.
3.6. Funnel Plot and Publication Bias. The funnel plot of HHS
and treatment failure rates were shown in Figures 8(a) and
8(b), respectively. Symmetrical Scatters were observed in the
funnel plot, manifesting the publication bias in the results
of HHS, and treatment failure rates events in various studies
were relatively low.
4. Discussion
How topostponeONFHprogression remains a challenge that
needs to be fully understood. Although there are varieties of
treatments for preserving the femoral head [18], the optimal
one is still controversial. In the present Bayesian network
meta-analysis study, we systematically analyzed the effects
of several hip preservation treatments on nontraumatic
ONFH, including ESW,CD,DD,VFG, FVFG, IFHG,VIPBG,
osteotomy, and TI.
CD is a standard technique widely used in patients with
early-stage ONFH, which helps to decrease intraosseous
pressure in the femoral head, reestablish vascular flow, and
relieve pain [19]. There were many studies that investigated
the efficacy of CD for the treatment of patients with early-
stage ONFH. Nevertheless, the clinical success of CD has
inconsistencies (from 47% to 83%), mainly related to many
different factors including causes and the stage of the lesion,
skill of procedures, and duration of follow-up [20–23]. Based
on our network results and rankings results, CD provided
a moderate outcome in terms of improving HHS and pre-
venting treatment failures as compared with other joint-
preserving treatments.
Some articles indicated that the conventional core
decompression might lead to further collapse of femur head
due to the weakening of subchondral bone support [24,
25]. To overcome the limitations of this surgery, multiple
drilling has been advocated. One research demonstrated that
multiple drilling effectively reduced the pressure of femoral
8 BioMed Research International
(a) Harris hip score (b) Treatment failure rates
(c) Treatment failure rates in stage-II
Figure 7: Forest plot of network consistency analysis for comparisons by node splitting method. Numbers represent the posterior
means and standard deviations (SDs) of the direct, indirect, and network estimates of the odds ratios (ORs) and rate ratios (RRs). CD:
core decompression; ESWT: extracorporeal shock wave; DD: multiple drilling decompression; VFG: vascularized fibular grafting; FVFG:
free-vascularized fibular grafting; IFHG: inverted femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone grafting; TI: tantalum
implantation.
head and meanwhile maintained the supportive role of the
subchondral bone to avoid fractures or collapse of the femoral
head [26]. However, DD did not show significant better effect
on both the improvement of HHS and the prevention of THA
progression than CD in our network study, though DD had
a higher probability to rank better from rankograms in these
two aspects.
Based on our network results and rankograms, we rec-
ommended ESW as one of the optimal interventions due to
its better efficacy and moderate safety in improving HHS.
The mechanism of ESW in the treatment of ONFH has not
been fully understood [2]. ESW was equipped to spread
to necrotic femoral hips, and a pressure loss of 50% of
shockwave was observed [27, 28]. Some researches proposed
that ESW could induce microfracture to accelerate bone
healing and enhance pain threshold [29–31]. Furthermore,
ESW promoted bone healing by enhancing osteogenesis and
angiogenesis as well as bone remodeling of diseased hips
[32, 33]. In this study, rankogram of ESW showed the highest
probability (52%) of being the best treatment in terms ofHHS
improvement. Increased range of motion and joint activity as
well as reduction of pain might be due to the promotion of
tissue remolding and the bluntness of pain sensation, which
would help the improvement of HHS. For the prevention of
collapse and THA progression, ESW also had a satisfactory
performance both in all stage and stage-II in rankogram,
indicating that ESW was one of the most optimal ways in
inhibiting progression.
The use of vascularized fibular graft was initiated in an
effort to arrest the progression of necrosis and to enhance
angiogenesis. The success of this surgical method was in
connection with multiple factors: (1) sufficient decompres-
sion, (2) mechanical support, and (3) augmentation with
additional cancellous bone graft. VFG not only provides
structural support, but also restores vascular supply to
enhance lesion healing [34, 35]. A report on the long-term
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ESWT: extracorporeal shock wave; DD: multiple drilling decompression; VFG: vascularized fibular grafting; FVFG: free-vascularized fibular
grafting; IFHG: inverted femoral head grafting (IFHG); VIPBG: vascular iliac pedicle bone grafting; TI: tantalum implantation.
results of VFG indicated that 49 of 65 hips (75%) survived
at a mean follow-up of fifteen years (range: 10.5–26.1 years)
[36]. Moreover, some studies suggested that VFG was a
better treatment option than CD and nonvascularized fibular
grafting due to the less dome depression of the femoral head
[37–39]. Our results showed VFG had significantly better
effect in improving HHS than DD and FVFG. Besides, it also
had a better outcome in terms of inhibiting collapse and THA
progression than DD, FVFG, and osteotomy. Meanwhile, the
rankogram showed VFG had the highest probability (59%)
of being the best treatment in preventing collapse and THA
progression. InHHS improvement, VFG had 39%probability
of being the best treatment and 50% probability of being the
second best treatment. Hence, we got the conclusion that
VFG would be one of the most optimal interventions.
TI has been used as reasonable mechanical substitute of
a fibular graft following CD for ONFH treatment [40]. The
tantalum implant aims to provide a structural scaffold for
bone ingrowth by its osteoconductive capacity [41]. However,
the effect of TI transplantation is still under debate. In one
study, 16 of 58 hips (28%) showed radiographic progression
and 9 of 58 hips (16%) converted to THA at a mean follow-
up of 24 months [42]. Tanzer M found the presence of
bone ingrowth in thirteen (87%) of the fifteen specimens
by backscattered scanning electron microscopy. The mean
extent of bone ingrowth was only 1.9% (range: 0% to 4.4%).
The retrieved implants were associated with limited bone
ingrowth and insufficient mechanical support of subchondral
bone [43]. Based on our study, TI did not have significantly
different effect as compared with DD and CD, yet the effect
of TI, DD, and CD was not as good as that of ESW and VFG.
Osteotomies aim to prevent femoral head collapse by
transposing the osteonecrotic area from a weight-bearing to
a non-weight-bearing area of the hip joint, thereby diverting
mechanical stress from the lesion to healthy bone. An earlier
study found that 28 hips (76 %) treated by intertrochanteric
varus osteotomy had a good or excellent result at a mean
follow-up of 11.5 years [44]. Another study indicated that
22 of 28 hips (79 %) treated by intertrochanteric rotational
osteotomy had survived with a mean HHS of 85.8 at the final
follow-up [45]. In recent years, the usage of osteotomy has
been reduced due to limited indications for small lesions.
Besides, osteotomies were associated with a higher rate of
complications, such as nonunion or delayed union and loss
of fixation and/or position, which also restricted the usage
of this technique [46]. Moreover, this surgical technique was
highly complicated, and it was difficult to convert the failed
cases to THA. Based on the available data from our network
analysis, we do not recommend this technology as the first
choice until the publication of long-term follow-up results.
IFHG and VIG are two alternative interventions for
ONFH. When IFHG was used, one cylindrical block of
cancellous bone was harvested from the femoral head and
then inverted and reinserted into the core. One study showed
the improvement of HHS by IFHG compared with CD,
although a proportion of patients experienced radiographic
progression [47]. When VIPBG technique was used, vascu-
larized iliac bone grafting was taken to replace the necrosis
region [48]. In our study, the two interventions did not show
significant difference in preventing collapse compared with
other interventions. In terms of HHS, VFG showed slightly
better outcome than IFHG.Thus, wewould recommendVFG
as a preferred choice for ONFH treatment compared with
IFHG and VIG.
As far as we know, this was the first comprehensive
network comparison ofmainstream interventions forONFH.
To compare the efficacy of nine treatments for ONFH, we
used a Bayesian network model to combine direct and
10 BioMed Research International
indirect evidence on the effectiveness in 14 RCTs. From the
analysis, we got the conclusion that VFG and ESW would
be the optimal choices for the treatment of early ONFH in
terms of improving HHS and preventing treatment failures.
We also analyzed the patients by disease stage to get a better
understanding of the efficacy of various interventions at
different disease stages. As far as preventing treatment failures
was concerned, VGF and ESW therapy also showed better
outcomes in stage-II.
Nevertheless, this study had several limitations. First of
all, only published studies were included in the present meta-
analysis. Thus, publication bias may have occurred. Secondly,
the heterogeneity existed in terms of risk factors, lesion
sizes and stages, bilateral versus unilateral disease, surgical
techniques, indications for THR, and follow-up time.Thirdly,
detailed blind methods and allocation concealment were not
described in some of the included RCTs, which could affect
the validity for overall findings. Furthermore, due to the
different classification measurements (radiographic evidence
based on X-ray and MRI) applied in various reports, the
reliability of the avascular necrosis status assessment was
decreased.
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